EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants

Agnes Hincelin-Mery iD, Xavier Nicolas iD, Cathy Cantalloube iD, Robert Pomponio iD, Pascale Lewanczyk iD, Myriam Benamor iD, Dimitry Ofengeim iD, Emmanuel Krupka iD, Jennifer Hsiao-Nakamoto iD, Amy Eastenson iD, Nazem Atassi iD

Clinical and Translational Science · 2024-01 · 17 (1)

DOI: 10.1111/cts.13690 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 11.12.2023. Verfasst von Agnes Hincelin-Mery und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Chilly-Mazarin, France. Hauptthemen laut MEDLINE: Brain, Receptor-Interacting Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SAR443820 (DNL788) is a selective, orally bioavailable, brain penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). This phase I first‐in‐human healthy participant study (NCT05795907) was comprised of three parts: randomized, double‐blind, placebo‐controlled single ascending dose (SAD; part 1a); 14‐day multiple ascending dose (MAD; part 2) parts that evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SAR443820; and a separate open‐label, single‐dose part 1b (PK‐cerebrospinal fluid [CSF]) to assess SAR443820 levels in CSF. SAR443820 was well‐tolerated in healthy participants, and no treatment discontinuation related to an adverse event (AE) occurred. Most common AEs were dizziness and headache. No clinically meaningful changes were noted in laboratory values, vital signs, or electrocardiogram parameters. SAR443820 had a favorable PK profile, with plasma half‐lives (geometric mean) ranged between 5.7–8.0 h and 7.2–8.9 h after single and repeated doses, respectively. There were no major deviations from dose proportionality for maximum concentration and area under the curve across SAR443820 doses. Mean CSF‐to‐unbound plasma concentration ratio ranged from 0.8 to 1.3 over time (assessed up to 10 h postdose), indicating high brain penetrance. High levels of inhibition of activated RIPK1, as measured by decrease in pS166‐RIPK1, were achieved in both SAD and MAD parts, with a maximum median inhibition from baseline close to 90% at predose (C trough ) after multiple dosing in MAD, reflecting a marked RIPK1 target engagement at the peripheral level. These results support further development of SAR443820 in phase II trials in amyotrophic lateral sclerosis (NCT05237284) and multiple sclerosis (NCT05630547).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrainReceptor-Interacting Protein Serine-Threonine KinasesAdultHumansHealthy VolunteersDose-Response Relationship, DrugArea Under CurveHalf-LifeDouble-Blind Method

Substanzen

RIPK1 protein, humanReceptor-Interacting Protein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Sanofi, Chilly-Mazarin, France.
  • Sanofi, Montpellier, France.
  • Sanofi, Cambridge, Massachusetts, USA.
  • Ividata Life Sciences, Levallois-Perret, France.
  • Denali Therapeutics Inc., South San Francisco, California, USA.
  • Nucleus Network Pty Ltd., St. Paul, Minnesota, USA.

ORCID-Profile: Agnes Hincelin-Mery, Xavier Nicolas, Cathy Cantalloube, Robert Pomponio, Pascale Lewanczyk, Myriam Benamor, Dimitry Ofengeim, Emmanuel Krupka, Jennifer Hsiao-Nakamoto, Amy Eastenson, Nazem Atassi

Zitieren

APA

Hincelin-Mery, A., Nicolas, X., Cantalloube, C., Pomponio, R., Lewanczyk, P., Benamor, M., Ofengeim, D., Krupka, E., Hsiao-Nakamoto, J., Eastenson, A., & Atassi, N. (2024). Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clinical and Translational Science, 17(1). https://doi.org/10.1111/cts.13690

Vancouver

Hincelin-Mery A, Nicolas X, Cantalloube C, Pomponio R, Lewanczyk P, Benamor M, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clinical and Translational Science. 2024;17(1). doi:10.1111/cts.13690

BibTeX
@article{HincelinMery2024,
  author = {Hincelin-Mery, Agnes and Nicolas, Xavier and Cantalloube, Cathy and Pomponio, Robert and Lewanczyk, Pascale and Benamor, Myriam and Ofengeim, Dimitry and Krupka, Emmanuel and Hsiao-Nakamoto, Jennifer and Eastenson, Amy and Atassi, Nazem},
  title = {Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.1111/cts.13690}
}
Kostenlos starten →